Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 7
Submit an article Journal homepage
39
Views
4
CrossRef citations to date
0
Altmetric
Commentary

Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy

Farhad Ravandi Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
Pages 1073-1074 | Received 19 Apr 2009, Accepted 24 Apr 2009, Published online: 21 Jul 2009

References

  • Pedersen-Bjergaard J, Rowley J D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–2786
  • Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002; 100: 1972–1976
  • Beaumont M, Sanz M, Carli P M, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123–2137
  • Mistry A R, Felix C A, Whitmarsh R J, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529–1538
  • Hasan S K, Mays A N, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112: 3383–3390
  • Aversa S ML, Trentin C, Sorarů M, et al. Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 1214–1216
  • Soignet S L, Frankel S R, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860
  • Mathews V, George B, Lakshmi K M, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–2632
  • Alimoghaddam K, Shariftabrizi A, Tavangar S M, et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma 2006; 47: 81–88
  • Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504–510
  • Ammatuna E, Montefusco E, Pacilli M, et al. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. Leuk Lymphoma 2009; 50: 1217–1218
  • Andersen M K, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002; 100: 1928–1929, author reply 1929, 2002
  • Garcia-Manero G, Kantarjian H M, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 2002; 16: 1888

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.